Imagine a world where a relentless blood cancer like multiple myeloma could be wiped out without the grueling ordeal of bone marrow transplants—sounds like science fiction, right? But here's where it gets exciting: groundbreaking antibody therapy is showing promise in eradicating even the tiniest traces of this disease in early trials, potentially transforming how we fight it. Stick around to discover how this innovative approach might spare patients from intense treatments and offer hope for long-term remission.
Antibody Therapy Clears All Signs of Multiple Myeloma in Early-Stage Study
By: Wynne Parry | December 06, 2025 | 7 min. read|
Summary
- Experts at Sylvester Comprehensive Cancer Center have demonstrated that a specialized antibody treatment, designed to activate the immune system against cancer cells, successfully eliminates lingering remnants of multiple myeloma.
- The therapy employs linvoseltamab, a drug that connects to CD3 on immune T cells and BCMA on myeloma cells, boosting the body's natural defenses to target the cancer.
- These initial encouraging outcomes from the trial indicate that linvoseltamab might enable patients to sidestep bone marrow transplants altogether.
In a promising development for those battling multiple myeloma—a form of blood cancer originating from plasma cells that produce antibodies—treatment with a targeted antibody that engages both immune and cancer cells has proven effective in clearing out any remaining traces of the disease. This finding comes from preliminary data in a clinical trial led by scientists at Sylvester Comprehensive Cancer Center, affiliated with the University of Miami Miller School of Medicine. (For more on multiple myeloma, visit: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center/treatments-and-services/hematologic-(blood)-cancers-/multiple-myeloma-)
Remarkably, not a single one of the 18 participants who underwent up to six rounds of the treatment with linvoseltamab showed any detectable evidence of the disease when checked via ultra-sensitive testing methods. This early triumph hints that linvoseltamab, classified as a bispecific antibody, could empower patients to bypass the need for bone marrow transplants (learn more at: https://umiamihealth.org/en/treatments-and-services/hematology/adult-bone-marrow-transplant), which typically require aggressive chemotherapy regimens. Moreover, it opens the door to potentially enhancing survival rates and quality of life for those affected by this incurable condition in the long run.
Principal investigator Dickran Kazandjian, M.D., a physician and professor specializing in myeloma at the Myeloma Division of the Miller School (profile available at: https://med.miami.edu/faculty/dickran-kazandjian-md), shared these updated findings today during the American Society of Hematology conference in Orlando. He collaborated on the study with C. Ola Landgren, M.D., Ph.D., who directs the Sylvester Myeloma Institute (see his profile at: https://med.miami.edu/faculty/c-ola-landgren-md-phd).
'Dr. Kazandjian explained, 'These individuals underwent cutting-edge, highly effective initial treatments that reduced their tumors by 90%. In the past, scenarios like this would lead to heavy-duty chemo followed by a transplant. But now, we're introducing linvoseltamab as an alternative.'
Dr. Landgren, who also serves as a professor and head of the Myeloma Division at the Miller School, described the results as 'incredibly impressive,' noting that the absence of persistent myeloma cells suggests brighter prospects ahead.
'From what I've seen in my career,' he added, 'I anticipate that with such a strong response in a relatively brief period, the cancer could remain at bay for decades. And for some, could it vanish forever? Absolutely, that's within the realm of possibility.'
Tracking Down and Tackling Hidden Cancer Cells
Multiple myeloma develops from plasma cells—specialized immune cells responsible for creating antibodies. When these cells turn malignant, they proliferate uncontrollably, crowding out healthy blood components and wreaking havoc on the body. Unfortunately, there's no definitive cure available yet. According to data from the U.S. National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, over 192,000 Americans were living with the disease in 2022, and projections for this year include around 36,000 new diagnoses.
Standard care for newly diagnosed patients often involves a regimen of three or four medications combined. While this can sometimes fully eliminate the cancerous cells, residual disease may persist undetected. These subtle leftovers are so minute that they evade routine bone marrow tests, which are like basic checks but not thorough enough for tiny amounts.
To uncover these minuscule cancer traces, specialists at Sylvester employ advanced bone marrow biopsy analysis using a technique that spots specific genetic markers linked to the malignancy. This method is extraordinarily precise, capable of detecting just one cancerous cell among a million healthy ones.
In medical terms, these rare surviving myeloma cells are referred to as minimal residual disease, or MRD (for in-depth info, check: https://news.med.miami.edu/cancer-research-in-the-wake-of-a-key-fda-decision-on-minimal-residual-disease/). Dr. Landgren, who was instrumental in establishing MRD as a benchmark for assessing novel treatments, points out that individuals who come back MRD-negative typically enjoy extended periods—often years—free from cancer recurrence compared to those who test positive (see related study: https://pmc.ncbi.nlm.nih.gov/articles/PMC7724898/).
For years, those with lingering disease (MRD-positive cases) have conventionally proceeded to high-dose chemotherapy post-combination therapy to eradicate the remaining cells. However, this approach brings severe side effects with it. To facilitate recovery, patients then undergo autologous stem cell transplantation, where their own blood-forming stem cells—harvested from bone marrow—are reinfused the next day.
Dr. Landgren described it as 'an extremely harsh procedure,' originally pioneered in the United Kingdom back in 1983.
Sadly, in the majority of instances, the myeloma resurfaces eventually. But here's the part most people miss: this cycle of relapse highlights why alternative strategies are crucial.
Towards a 'Functional Cure' for Multiple Myeloma
This ongoing phase 2 clinical trial, carried out at Sylvester and its affiliated locations in Coral Gables and Deerfield Beach, has recruited 25 participants who were MRD-positive after standard combination therapies. These volunteers receive either four or six treatment cycles with linvoseltamab.
Unlike typical antibodies that latch onto just one target, bispecific ones like linvoseltamab connect to two. It targets CD3, a marker on T cells—the immune warriors that demolish harmful cells—and BCMA, found on multiple myeloma cells. By bridging these elements, the antibody revs up the body's immune attack against the cancer, acting like a clever matchmaker that brings fighters right to the enemy.
A handful of participants reported mild side effects, such as lowered white blood cell counts (neutropenia) and upper respiratory infections, but these remained within safe limits as per Dr. Kazandjian's assessment.
The team implemented proactive steps to prevent two serious complications—cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome—that can sometimes arise with similar immunotherapies. Fortunately, none of the participants in this study encountered these issues. Following treatment, MRD was evaluated in their bone marrow using two separate, highly accurate tests, and no disease remnants were detected in anyone who finished the full course.
Given these outcomes, Dr. Kazandjian is optimistic that linvoseltamab could deliver more lasting benefits than transplants, possibly leading to sustained disease control—a concept he calls a 'functional cure.'
'Yes, it's an ambitious assertion,' he remarked, 'but aiming high is essential to advance the field. That's precisely our goal.'
But here's where it gets controversial: Is calling this a 'cure' jumping the gun when the disease has historically proven stubborn and relapsing? Some might argue that labeling it prematurely could raise false hopes, while others see it as the bold vision needed to push boundaries. After all, transplants have been the gold standard for decades—could this antibody therapy truly replace them without long-term data? And this is the part most people miss: in an era where cancer treatments are evolving rapidly, how do we balance innovation with patient expectations?
Further validation will demand larger-scale studies with extended follow-up over several years. The investigators are already progressing by increasing enrollment to 50 participants.
What do you think? Does the potential for a 'functional cure' without transplants excite you, or does it raise red flags about overhyped promises? Share your thoughts in the comments—do you agree this could revolutionize myeloma care, or disagree that we're ready to ditch established methods? We'd love to hear your perspective!
Tags: ASH 2025 (https://news.med.miami.edu/tag/ash-2025/) , bone marrow transplant (https://news.med.miami.edu/tag/bone-marrow-transplant/) , cancer research (https://news.med.miami.edu/tag/cancer-research/) , Dr. C. Ola Landgren (https://news.med.miami.edu/tag/dr-c-ola-landgren/) , Dr. Dickran Kazandjian (https://news.med.miami.edu/tag/dr-dickran-kazandjian/) , immune system (https://news.med.miami.edu/tag/immune-system/) , minimal residual disease (https://news.med.miami.edu/tag/minimal-residual-disease/) , multiple myeloma (https://news.med.miami.edu/tag/multiple-myeloma/) , myeloma (https://news.med.miami.edu/tag/myeloma/) , Myeloma Research Institute (https://news.med.miami.edu/tag/myeloma-research-institute/) , Sylverster Comprehensive Cancer Center (https://news.med.miami.edu/tag/sylverster-comprehensive-cancer-center/)
